SCHEMBL21608271

SCHEMBL21608271

CCCCn1ccc2c(Br)nccc21

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.48
HTT P42858 2/20 0.48
TSHR P16473 1/20 0.48
KDM4E B2RXH2 3/20 0.44
MAPT P10636 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 2/20 0.44
POLB P06746 1/20 0.44
TLR8 Q9NR97 2/20 0.38
GRIN2B Q13224 1/20 0.37
KLKB1 P03952 1/20 0.37
KLK1 P06870 1/20 0.37
UTS2R Q9UKP6 1/20 0.35
HPGD P15428 1/20 0.34
HRH4 Q9H3N8 1/20 0.34
GRM2 Q14416 2/20 0.33
MPO P05164 1/20 0.33
ABCB1 P08183 1/20 0.33
DYRK1A Q13627 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21608343 0.83 LMNA (0.49) LMNAHTTTSHRKDM4EMAPT
SCHEMBL21603424 0.81 LMNA (0.48) LMNAHTTTSHRKDM4EMAPT
SCHEMBL21603462 0.81 LMNA (0.48) LMNAHTTTSHRKDM4EMAPT
SCHEMBL21608301 0.76 ALDH1A1 (0.44) LMNAHTTTSHRKDM4EMAPT
SCHEMBL21608286 0.76 NFATC1 (0.39) LMNAHTTTSHRKLKB1KLK1
SCHEMBL21608282 0.76 HTR2C (0.36) LMNAHTTTSHRSMN1; SMN2
SCHEMBL21608438 0.75 LMNA (0.34) LMNAHTTTSHRKDM4EMAPT
SCHEMBL21608260 0.75 CNR2 (0.35) ALDH1A1KMT2APOLBKLKB1KLK1
SCHEMBL24036270 0.74 MAPT (0.37) TSHRKDM4EMAPTALDH1A1
SCHEMBL23791696 0.74 KLKB1 (0.38) LMNAHTTTSHRKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210277003-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-09-09 US disclosed
WO-2019243535-A1 OGA INHIBITOR COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210277003-A1 OGA INHIBITOR COMPOUNDS OGA, OGT, GRN LMNA 848/4885HTT 33/4885TSHR 4632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.